Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Forecasted Market Size Estimates For The Tardive Dyskinesia Treatment Market Between 2025 And 2029?
The tardive dyskinesia treatment market size has experienced significant expansion in recent years. This market is projected to expand from $2.40 billion in 2024 to $2.61 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.7%. The historical period’s expansion can be ascribed to several factors, including the increasing application of antipsychotic medications, heightened recognition of drug-induced movement disorders, an uptick in the prevalence of schizophrenia and bipolar disorders, the rising off-label utilization of antipsychotics, and an expanding elderly demographic using psychotropic drugs.
The tardive dyskinesia treatment market is projected to experience robust expansion over the coming years. This market is set to reach $3.61 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.4%. This anticipated growth is driven by several factors, including an increasing demand for safer antipsychotic treatments, enhanced awareness fostered by advocacy and educational initiatives, a greater emphasis on tailored mental health solutions, increased healthcare expenditure allocated to neurological and psychiatric conditions, and an expanding population of psychiatric patients undergoing prolonged therapy. Key trends anticipated during this period encompass the development of neuroprotective approaches, the creation of dual-action therapies, the incorporation of real-world evidence (RWE) into drug assessment, the integration of digital biomarkers, and advancements in non-dopaminergic therapeutics.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27431&type=smp
What Are The Emerging Market Drivers Creating New Opportunities In The Tardive Dyskinesia Treatment Industry?
A rise in the occurrence of psychiatric disorders is anticipated to stimulate the expansion of the tardive dyskinesia treatment market in the future. Psychiatric disorders encompass diverse mental health issues impacting an individual’s mood, thought processes, conduct, and general functionality, frequently necessitating professional diagnosis and intervention. The frequency of psychiatric disorders is increasing, attributed to heightened stress and modern lifestyle demands stemming from intense workloads, feelings of social isolation, and insufficient time for personal well-being. Tardive dyskinesia treatment aids in controlling involuntary movement symptoms, thereby enhancing overall therapeutic results and the quality of life for patients with psychiatric disorders needing prolonged antipsychotic medication. For example, in March 2024, the House of Commons Library, a UK-based research and information service, reported that in 2022, the percentage of 17- to 19-year-olds with a probable mental disorder rose from 17% in 2021 to 26%. Consequently, the growing incidence of psychiatric disorders is fueling the expansion of the tardive dyskinesia treatment market.
What Are The Major Segment Types Covered In The Tardive Dyskinesia Treatment Market?
The tardive dyskinesia treatment market covered in this report is segmented
1) By Treatment Type: Medications, Botulinum Toxin Injections, Deep Brain Stimulation, Other Treatment Types
2) By Drug: Valbenazine, Amantadine, Tetrabenazine, Clonazepam, Other Drugs
3) By Route Of Administration: Oral Administration, Injection, Transdermal Patches
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
5) By End-Users: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Medications: Antipsychotic Medications, Benzodiazepines, Dopamine-Depleting Agents, Anticholinergic Agents
2) By Botulinum Toxin Injections: Facial Muscle Injections, Neck Muscle Injections, Limb Muscle Injections, Customized Injection Protocols
3) By Deep Brain Stimulation: Subthalamic Nucleus Stimulation, Globus Pallidus Interna Stimulation, Thalamic Stimulation, Multi-Target Stimulation
4) By Other Treatment Types: Supportive Therapies, Cognitive Behavioral Therapy, Physical Rehabilitation, Emerging Experimental Treatments
Which Trends Are Impacting The Tardive Dyskinesia Treatment Market?
Major companies operating in the tardive dyskinesia treatment market are focusing on developing innovative drugs, such as sprinkle capsule formulations, to improve medication adherence for patients with swallowing difficulties. Sprinkle capsule formulations are medications designed to be opened and sprinkled onto soft food, making them easier to swallow for patients with dysphagia or difficulty taking whole capsules. For instance, in July 2024, Neurocrine Biosciences Inc., a US-based biotechnology company, launched Ingrezza sprinkle (valbenazine) capsules, the leading prescribed vesicular monoamine transporter 2 (VMAT2) inhibitor for treating adults with tardive dyskinesia and chorea associated with Huntington’s disease. This VMAT2 inhibitor works by regulating dopamine levels in the brain to help manage involuntary movements. The medication is available as a once-daily oral capsule, including a sprinkle formulation designed to ease administration for patients who have difficulty swallowing.
Which Major Firms Are Strengthening Their Position In The Tardive Dyskinesia Treatment Industry?
Major companies operating in the tardive dyskinesia treatment market are AbbVie Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Jazz Pharmaceuticals plc, Kyowa Kirin Co Ltd., H. Lundbeck A/S, Zydus Lifesciences Limited, Neurocrine Biosciences Inc., Luye Pharma Group Ltd., Acadia Pharmaceuticals Inc., Upsher-Smith Laboratories LLC, SteriMax Inc., Adamas Pharmaceuticals Inc., ChemWerth Inc, Sunovion Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Synnat Pharma Pvt. Ltd, LGM Pharma LLC, and SOM Biotech S.A.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/tardive-dyskinesia-treatment-global-market-report
Which Global Regions Are Influencing The Competitive Landscape Of The Tardive Dyskinesia Treatment Market?
North America was the largest region in the tardive dyskinesia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tardive dyskinesia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Tardive Dyskinesia Treatment Market Report:
https://www.thebusinessresearchcompany.com/customise?id=27431&type=smp
Browse Through More Reports Similar to the Global Tardive Dyskinesia Treatment Market 2025, By The Business Research Company
Tax Preparation Services Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/tax-preparation-services-global-market-report
Tax Management Software Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/tax-management-software-global-market-report
Tax Management Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/tax-management-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model